Kynamro Side Effects

Generic name: mipomersen

Medically reviewed by Drugs.com. Last updated on May 9, 2024.

Note: This document provides detailed information about Kynamro Side Effects associated with mipomersen. Some dosage forms listed on this page may not apply specifically to the brand name Kynamro.

Applies to mipomersen: subcutaneous solution.

Important warnings This medicine can cause some serious health issues

Mipomersen is available only from a certified pharmacy.

You should not use mipomersen if you have active liver disease or abnormal liver function tests. Tell your doctor right away if you have liver symptoms, such as vomiting, fever, stomach pain, itching, tiredness, dark urine, or jaundice (yellowing of the skin or eyes).

Mipomersen can cause your liver enzymes to get too high. Your blood will need to be tested often. Your treatments may be stopped based on the results of these tests.

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Stop using mipomersen (the active ingredient contained in Kynamro) and call your doctor at once if you have:

• flu symptoms within 2 days after an injection--fever, chills, body aches, tired feeling, joint or muscle pain;

• pain, swelling, redness, itching, bruising, or tenderness where an injection was given; or

• nausea, upper stomach pain, itching, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).

Common side effects may include:

• nausea;

• headache; or

• flu symptoms.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.

For healthcare professionals

Applies to mipomersen: subcutaneous solution.

Cardiovascular

• Common (1% to 10%): Hypertension (7%), angina pectoris (4%), palpitations (3%)^[Ref]

Dermatologic

• Very common (10% or more): [All injection site reactions (84%)], erythema (59%), pain (56%), hematoma (32%), pruritus (29%), swelling (18%), discoloration (17%)^[Ref]

Gastrointestinal

• Very common (10% or more): Nausea (14%)
• Common (1% to 10%): Vomiting (4%), abdominal pain (3%)^[Ref]

Hepatic

• Very common (10% or more): Alanine aminotransferase (ALT) increased (10%)
• Common (1% to 10%): Hepatic steatosis (7%), aspartate aminotransferase (AST) increased (6%), liver function test abnormal (5%), hepatic enzyme increased (3%)^[Ref]

Immunologic

• Rare (less than 0.1%): One case of hypersensitivity with angioedema was reported^[Ref]

Metabolic

• Common (1% to 10%): Proteinuria (9%), peripheral edema (5%)^[Ref]

Musculoskeletal

• Common (1% to 10%): Pain in extremity (7%), musculoskeletal pain (4%)^[Ref]

Nervous system

• Very common (10% or more): Fatigue (15%), headache (12%)
• Common (1% to 10%): Pyrexia (8%), chills (6%)^[Ref]

Oncologic

• Common (1% to 10%): Neoplasms [benign and malignant] (4%)^[Ref]

Psychiatric

• Common (1% to 10%): Insomnia (3%)^[Ref]

Renal

• Rare (less than 0.1%): One case of glomerular nephritis was reported^[Ref]

Further information

Kynamro side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Medical Disclaimer